

Special Issue

Unlocking Precision and Minimizing Morbidity: Sentinel Lymph Node Mapping in Gynecological Cancer

Message from the Guest Editor

Sentinel lymph node (SLN) mapping has revolutionized the assessment and management of gynecological cancer by providing crucial prognostic information while minimizing treatment-related morbidity. SLN biopsy has transformed the traditional lymph node evaluation paradigm for early stage vulvar, cervical, and endometrial cancers, where nodal status carries significant prognostic implications. With the goal of removing the primary tumor and accurately staging regional lymph nodes, SLN biopsy offers a promising alternative to extensive lymphadenectomies, which are often associated with substantial morbidity. For vulvar cancer, level 3 evidence supports the safety of omitting inguinofemoral lymphadenectomy when the sentinel node is negative. Similarly, for clinical early stage endometrial and cervical cancer, acceptable false-negative rates have been observed, indicating the potential clinical utility and safety of SLN biopsy. We anticipate that SLN mapping will become an integral component of the standard of care, improving outcomes and enhancing the quality of life for women facing gynecological malignancies.

Guest Editor

Dr. Petra L.M. Zusterzeel
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Deadline for manuscript submissions

closed (30 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/178969

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)